Results 1 to 10 of about 8,266,387 (310)

CAR-T Therapies in Solid Tumors: Opportunities and Challenges

Current Oncology Reports, 2023
Purpose of Review This review will discuss the challenges facing chimeric antigen receptor (CAR)-T cell application for solid tumors and opportunities to overcome these obstacles.
Brian Koss, Analiz Rodriguez, Megan Reed
exaly   +2 more sources

Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma

Disease Models & Mechanisms, 2022
There is a paucity of adequate mouse models and cell lines available to study lung squamous cell carcinoma (LUSC). We have generated and characterized two models of phenotypically different transplantable LUSC cell lines, i.e.
Karmele Valencia, Cristina Sainz, Cristina Bértolo, Gabriel de Biurrun, Jackeline Agorreta, Arantza Azpilikueta, Marta Larrayoz, Graziella Bosco, Carolina Zandueta, Miriam Redrado, Esther Redín, Francisco Exposito, Diego Serrano, Mirari Echepare, Daniel Ajona, Ignacio Melero, Ruben Pio, Roman Thomas, Alfonso Calvo, Luis M. Montuenga   +19 more
doaj   +1 more source

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

Journal of Clinical Oncology, 2023
PURPOSE Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)–directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers and HER2-mutant non–small-cell lung cancer.
F. Meric-Bernstam, V. Makker, A. Oaknin, Do-Youn Oh, Susana N. Banerjee, A. González-Martín, K. Jung, I. Ługowska, L. Manso, A. Manzano, B. Melichar, S. Siena, D. Stroyakovskiy, A. Fielding, Yan Ma, S. Puvvada, Norah J. Shire, Jung-Yun Lee   +17 more
semanticscholar   +1 more source

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.

New England Journal of Medicine, 2023
BACKGROUND Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity. METHODS In a phase 1 study, we evaluated divarasib administered orally once daily (at doses ranging from 50 to 400 mg) in patients
A. Sacher, P. Lorusso, M. Patel, Wilson H. Miller, E. Garralda, Martin D. Forster, A. Santoro, A. Falcón, Tae Won Kim, L. Paz-Ares, S. Bowyer, M. D. de Miguel, Sae-Won Han, M. Krebs, Jong-Seok Lee, Michael L. Cheng, K. Arbour, E. Massarelli, Yoonha Choi, Zhengrong Shi, S. Mandlekar, Mark T. Lin, S. Royer-Joo, Julie Chang, N. Dharia, J. Schutzman, Jayesh Desai   +26 more
semanticscholar   +1 more source

Extracellular vesicles from subjects with COPD modulate cancer initiating cells phenotype through HIF-1α shuttling

Cell Death and Disease, 2023
Chronic obstructive pulmonary disease (COPD) is a risk factor for lung cancer development. COPD induces activation of hypoxia-induced signaling, causing remodeling of surrounding microenvironmental cells also modulating the release and cargo of their ...
Ilaria Petraroia, Patrizia Ghidotti, Giulia Bertolini, Francesca Pontis, Luca Roz, Melissa Balsamo, Paola Suatoni, Ugo Pastorino, Anna Maria Ferretti, Gabriella Sozzi, Orazio Fortunato   +10 more
doaj   +1 more source

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

Journal for ImmunoTherapy of Cancer, 2021
Introduction The use of immune-checkpoint inhibitors has drastically improved the management of patients with non-small cell lung cancer (NSCLC), but innate and acquired resistances are hurdles needed to be solved.
Jackeline Agorreta, Ana Remirez, Ruben Pio, Luis M Montuenga, Teresa Lozano, Esther Redin, Irati Garmendia, Diego Serrano, Yaiza Senent, Miriam Redrado, Maria Villalba, Francisco Exposito, Daniel Ajona, Sergio Ortiz-Espinosa, Cristina Bertolo, Cristina Sainz, Juana Garcia-Pedrero, Juan Lasarte, Alfonso Calvo   +18 more
doaj   +1 more source

Improving high-resolution copy number variation analysis from next generation sequencing using unique molecular identifiers

BMC Bioinformatics, 2021
Background Recently, copy number variations (CNV) impacting genes involved in oncogenic pathways have attracted an increasing attention to manage disease susceptibility.
Pierre-Julien Viailly, Vincent Sater, Mathieu Viennot, Elodie Bohers, Nicolas Vergne, Caroline Berard, Hélène Dauchel, Thierry Lecroq, Alison Celebi, Philippe Ruminy, Vinciane Marchand, Marie-Delphine Lanic, Sydney Dubois, Dominique Penther, Hervé Tilly, Sylvain Mareschal, Fabrice Jardin   +16 more
doaj   +1 more source

Gene expression profiles of breast cancer metastasis according to organ site

Molecular Oncology, 2022
In advanced breast cancer, biomarker identification and patient selection using a metastatic tumor biopsy is becoming more necessary. However, the biology of metastasis according to the organ site is largely unknown.
Fara Brasó‐Maristany, Laia Paré, Nuria Chic, Olga Martínez‐Sáez, Tomás Pascual, Meritxell Mallafré‐Larrosa, Francesco Schettini, Blanca González‐Farré, Esther Sanfeliu, Débora Martínez, Patricia Galván, Esther Barnadas, Belinda Salinas, Pablo Tolosa, Eva Ciruelos, Esther Carcelero, Cecilia Guillén, Barbara Adamo, Reinaldo Moreno, Maria Vidal, Montserrat Muñoz, Aleix Prat   +21 more
doaj   +1 more source

Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation

Journal of Clinical Oncology, 2023
PURPOSE Adagrasib, a KRASG12C inhibitor, has demonstrated clinical activity in patients with KRASG12C-mutated non–small-cell lung cancer (NSCLC) and colorectal cancer (CRC). KRASG12C mutations occur rarely in other solid tumor types. We report evaluation
T. Bekaii-Saab, R. Yaeger, A. Spira, M. Pelster, J. Sabari, Navid Hafez, M. Barve, K. Velastegui, Xiao-Hong Yan, A. Shetty, H. Der-Torossian, S. Pant   +11 more
semanticscholar   +1 more source

TCR-engineered T cell therapy in solid tumors: State of the art and perspectives

Science Advances, 2023
T cell engineering has changed the landscape of cancer immunotherapy. Chimeric antigen receptor T cells have demonstrated a remarkable efficacy in the treatment of B cell malignancies in hematology. However, their clinical impact on solid tumors has been
Estelle Baulu, Célia Gardet, N. Chuvin, S. Depil   +3 more
semanticscholar   +1 more source